MONTELUKAST SODIUM vs ZAFIRLUKAST

Compare MONTELUKAST SODIUM (montelukast sodium) and ZAFIRLUKAST (Zafirlukast) — clinical data, side effects, and patient experiences.

MONTELUKAST SODIUM

montelukast sodium · Leukotriene Modifier

How it works

12.1 Mechanism of Action The cysteinyl leukotrienes (LTC 4 , LTD 4 , LTE 4 ) are products of arachidonic acid metabolism and are released from various cells, including mast cells a...

Approved for

reserve use for patients who have an inadequate response or intolerance to alternative therapies.

OralTablet

ZAFIRLUKAST

Zafirlukast · Leukotriene Modifier

How it works

Leukotriene Modifier agent

Approved for

INDICATIONS AND USAGE Zafirlukast is indicated for the prophylaxis and chronic treatment of asthma in adults and children 5 years of age and older.

OralTablet

Quick Comparison

MONTELUKAST SODIUMZAFIRLUKAST

Drug Class

Leukotriene Modifier

Route

Oral

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

MONTELUKAST SODIUM

Shortness of Breath

>10%

Drug Not Working

1-10%

Fatigue

1-10%

Cough

1-10%

Headache

1-10%

Nausea

1-10%

Anxiety

0.1-1%

Diarrhea

0.1-1%

ZAFIRLUKAST

Shortness of Breath

>10%

Fatigue

1-10%

Drug Not Working

1-10%

Cough

1-10%

Nausea

1-10%

Headache

1-10%

Rash

1-10%

Itching

1-10%

FDA Warnings

MONTELUKAST SODIUM

5 WARNINGS AND PRECAUTIONS • Do not prescribe montelukast sodium to treat an acute asthma attack ( 5
1 Neuropsychiatric Events Serious neuropsychiatric (NP) events have been reported with of montelukast sodium
Based upon the available data, it is difficult to identify risk for or quantify the risk of NP events with montelukast sodium use
Because of the risk NP events, the benefits of montelukast sodium may not outweigh the risks in some patients, particularly when the symptoms of disease may be mild and adequately with alternative therapies

ZAFIRLUKAST

WARNINGS Hepatotoxicity Cases of life-threatening hepatic failure have been reported in patients treated with zafirlukast
In rare cases, patients have either presented with fulminant hepatitis or progressed to hepatic failure, liver transplantation and death
Periodic serum transaminase testing has not proven to prevent serious injury but it is generally believed that early detection of drug-induced hepatic injury along with immediate withdrawal of the suspect drug enhances the likelihood for recovery

Clinical Trial Data

No head-to-head clinical studies found for MONTELUKAST SODIUM vs ZAFIRLUKAST.

MONTELUKAST SODIUM vs ZAFIRLUKAST: What You Should Know

Key Differences

Both MONTELUKAST SODIUM and ZAFIRLUKAST belong to the Leukotriene Modifier class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients.

Safety Considerations

MONTELUKAST SODIUM carries 4 FDA warnings. ZAFIRLUKAST carries 3 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

MONTELUKAST vs MONTELUKAST SODIUM→MONTELUKAST vs ZAFIRLUKAST→

Loading comparison data...

MONTELUKAST SODIUM vs ZAFIRLUKAST

Compare MONTELUKAST SODIUM (montelukast sodium) and ZAFIRLUKAST (Zafirlukast) — clinical data, side effects, and patient experiences.

MONTELUKAST SODIUM

montelukast sodium · Leukotriene Modifier

How it works

12.1 Mechanism of Action The cysteinyl leukotrienes (LTC 4 , LTD 4 , LTE 4 ) are products of arachidonic acid metabolism and are released from various cells, including mast cells a...

Approved for

reserve use for patients who have an inadequate response or intolerance to alternative therapies.

OralTablet

ZAFIRLUKAST

Zafirlukast · Leukotriene Modifier

How it works

Leukotriene Modifier agent

Approved for

INDICATIONS AND USAGE Zafirlukast is indicated for the prophylaxis and chronic treatment of asthma in adults and children 5 years of age and older.

OralTablet

Quick Comparison

MONTELUKAST SODIUMZAFIRLUKAST

Drug Class

Leukotriene Modifier

Route

Oral

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

MONTELUKAST SODIUM

Shortness of Breath

>10%

Drug Not Working

1-10%

Fatigue

1-10%

Cough

1-10%

Headache

1-10%

Nausea

1-10%

Anxiety

0.1-1%

Diarrhea

0.1-1%

ZAFIRLUKAST

Shortness of Breath

>10%

Fatigue

1-10%

Drug Not Working

1-10%

Cough

1-10%

Nausea

1-10%

Headache

1-10%

Rash

1-10%

Itching

1-10%

FDA Warnings

MONTELUKAST SODIUM

5 WARNINGS AND PRECAUTIONS • Do not prescribe montelukast sodium to treat an acute asthma attack ( 5
1 Neuropsychiatric Events Serious neuropsychiatric (NP) events have been reported with of montelukast sodium
Based upon the available data, it is difficult to identify risk for or quantify the risk of NP events with montelukast sodium use
Because of the risk NP events, the benefits of montelukast sodium may not outweigh the risks in some patients, particularly when the symptoms of disease may be mild and adequately with alternative therapies

ZAFIRLUKAST

WARNINGS Hepatotoxicity Cases of life-threatening hepatic failure have been reported in patients treated with zafirlukast
In rare cases, patients have either presented with fulminant hepatitis or progressed to hepatic failure, liver transplantation and death
Periodic serum transaminase testing has not proven to prevent serious injury but it is generally believed that early detection of drug-induced hepatic injury along with immediate withdrawal of the suspect drug enhances the likelihood for recovery

Clinical Trial Data

No head-to-head clinical studies found for MONTELUKAST SODIUM vs ZAFIRLUKAST.

MONTELUKAST SODIUM vs ZAFIRLUKAST: What You Should Know

Key Differences

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.